Asset Details
Do you wish to reserve the book?
Neutralising antibodies against interferon beta in multiple sclerosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Neutralising antibodies against interferon beta in multiple sclerosis
Do you wish to request the book?
Neutralising antibodies against interferon beta in multiple sclerosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Neutralising antibodies against interferon beta in multiple sclerosis
2004
Overview
Sir Per Soelberg Sorensen and colleagues' study (Oct 11, p 1184)1 of the effects of neutralising antibodies against interferon beta on the clinical efficacy of interferon beta in patients with multiple sclerosis is flawed by a methodological tautology. Sorensen and colleagues use the effect of neutralising antibodies on relapse rate to define a clinically relevant titre, and then use the same cohort of patients to claim that neutralising antibodies affect the clinical efficacy of interferon beta. [...]it would be interesting to know whether the persistence of neutralising antibodies depended on the neutra-lising antibody titre, as found in earlier smaller series.5 In our opinion, a change of treatment should be considered in clinically active patients who are neutralising antibody negative, because clinical activity in such patients is not caused by a neutralising-antibody-mediated reduction of interferon beta efficacy, but probably by a genuine non-responsiveness to this treatment.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Antibody Formation - immunology
/ Humans
/ Immunologic Factors - immunology
/ Immunologic Factors - therapeutic use
/ Interferon-beta - immunology
/ Interferon-beta - therapeutic use
/ Multiple Sclerosis - drug therapy
/ Multiple Sclerosis - immunology
/ Neutralization Tests - statistics & numerical data
